These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 18006294

  • 1. Cytochromes P450 and drug discovery.
    Lamb DC, Waterman MR, Kelly SL, Guengerich FP.
    Curr Opin Biotechnol; 2007 Dec; 18(6):504-12. PubMed ID: 18006294
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Protein dynamics and imidazole binding in cytochrome P450 enzymes.
    Verras A, Ortiz de Montellano PR.
    Biochem Soc Trans; 2006 Dec; 34(Pt 6):1170-2. PubMed ID: 17073778
    [Abstract] [Full Text] [Related]

  • 4. Generalized proteochemometric model of multiple cytochrome p450 enzymes and their inhibitors.
    Kontijevskis A, Komorowski J, Wikberg JE.
    J Chem Inf Model; 2008 Sep; 48(9):1840-50. PubMed ID: 18693719
    [Abstract] [Full Text] [Related]

  • 5. Cytochrome P450s in the development of target-based anticancer drugs.
    Purnapatre K, Khattar SK, Saini KS.
    Cancer Lett; 2008 Jan 18; 259(1):1-15. PubMed ID: 18053638
    [Abstract] [Full Text] [Related]

  • 6. Mechanisms and significance of inhibitory drug interactions involving cytochrome P450 enzymes (review).
    Murray M.
    Int J Mol Med; 1999 Mar 18; 3(3):227-38. PubMed ID: 10028046
    [Abstract] [Full Text] [Related]

  • 7. Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.
    Appiah-Opong R, de Esch I, Commandeur JN, Andarini M, Vermeulen NP.
    Eur J Med Chem; 2008 Aug 18; 43(8):1621-31. PubMed ID: 18249473
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prediction of drug-like molecular properties: modeling cytochrome p450 interactions.
    Jalaie M, Arimoto R, Gifford E, Schefzick S, Waller CL.
    Methods Mol Biol; 2004 Aug 18; 275():449-520. PubMed ID: 15141126
    [Abstract] [Full Text] [Related]

  • 11. QSAR of cytochrome inhibitors.
    Roy K, Roy PP.
    Expert Opin Drug Metab Toxicol; 2009 Oct 18; 5(10):1245-66. PubMed ID: 19708826
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Cytochromes P450: xenobiotic metabolism, regulation and clinical importance].
    Guéguen Y, Mouzat K, Ferrari L, Tissandie E, Lobaccaro JM, Batt AM, Paquet F, Voisin P, Aigueperse J, Gourmelon P, Souidi M.
    Ann Biol Clin (Paris); 2006 Oct 18; 64(6):535-48. PubMed ID: 17162257
    [Abstract] [Full Text] [Related]

  • 17. Human CYPs involved in drug metabolism: structures, substrates and binding affinities.
    Lewis DF, Ito Y.
    Expert Opin Drug Metab Toxicol; 2010 Jun 18; 6(6):661-74. PubMed ID: 20402561
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.